Biogen (BIIB) News Today

Biogen Inc. (Nasdaq: BIIB) shares are reacting to a series of pipeline updates, strategic collaborations and capacity investments announced over the past 24 hours. Investors are weighing progress in Alzheimer’s research, a new rare-disease partnership, and plans to expand manufacturing alongside recent analyst coverage.

• Positive Sentiment: Biogen will present key data on its Alzheimer’s treatments at the upcoming Alzheimer’s Association International Conference—including 48-month Clarity AD long-term results for LEQEMBI® (lecanemab), real-world treatment insights, a subcutaneous formulation for maintenance dosing, and new tau-targeted therapy biomarker data. Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at AAIC 2025
• Positive Sentiment: Biogen has partnered with Stoke Therapeutics to develop treatments for Dravet syndrome, expanding its rare and pediatric neurology pipeline and strengthening longer-term growth prospects. Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome
• Neutral Sentiment: Biogen plans to invest an additional $2 billion to expand its Research Triangle Park manufacturing footprint, modernizing facilities with AI-driven automation and boosting antisense oligonucleotide and fill-finish capacity. Biogen to Invest $2 Billion More in North Carolina
• Neutral Sentiment: Truist Financial initiated coverage of BIIB with a “hold” rating and a $142 price target, implying modest upside from current levels but signaling tempered near-term expectations. Biogen (NASDAQ:BIIB) Now Covered by Analysts at Truist Financial
• Neutral Sentiment: Biogen completed its Phase 3 pediatric relapsing-remitting MS study, marking a key clinical milestone while full data readouts and regulatory discussions are still pending. Biogen’s Pediatric RRMS Study Completion: Market Implications and Insights